Key result
Essential hypertension is not associated with altered plasma endothelin levels compared to normotensive controls.
Case-Control
A radioimmunoassay has been developed for measuring endothelin-like immunoreactivity in human plasma using an antibody raised against endothelin-1 which also cross-reacts with big endothelin-1 and endothelin-2 but not endothelin-3. 2. The sensitivity of the assay was 1 fmol/tube with inter- and intra-assay coefficients of variation of 13% and 9%, respectively. Cross-reactivity with endothelin-3 and non-endothelin peptides was less than 1%. 3. Endothelin-like immunoreactivity was present in the plasma of hypertensive patients (n = 25) at a concentration of 5.7 +/- 0.5 pmol/l (mean +/- SEM), which was not significantly different from that of age-matched control subjects (5.1 +/- 0.5 pmol/l). At these levels, endothelin-1 is unlikely to function as a circulating hormone. 4. Within the normotensive group, the concentration of endothelin-like immunoreactivity in plasma was positively correlated with mean arterial blood pressure, but in hypertensive patients it showed a significant negative correlation.
No takes yet. Share an insight, caveat, or question.
Davenport et al. (1990) conducted a case-control in Essential hypertension. Essential hypertension vs. Age-matched normotensive control subjects was evaluated on Plasma concentration of endothelin-like immunoreactivity (pmol/l). Essential hypertension was not associated with significantly different plasma endothelin-like immunoreactivity compared with normotensive controls (5.7 vs 5.1 pmol/l).
Synapse has enriched 5 related papers. Consider them for comparative context: